1 / 29

Topical glaucoma medication with a teal cap?

Topical glaucoma medication with a teal cap?. Prostaglandin analogues Xalatan ® ( latanoprost ) 0.005% qd Travatan®(travoprost ) 0.004% qd Lumigan ® ( bimatoprost ) 0.03% qd. Mechanism of action: Prostaglandin analogues. Enhances uveoscleral outflow.

garry
Download Presentation

Topical glaucoma medication with a teal cap?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Topical glaucoma medication with a teal cap? • Prostaglandin analogues • Xalatan® (latanoprost) 0.005% qd • Travatan®(travoprost) 0.004% qd • Lumigan® (bimatoprost) 0.03% qd

  2. Mechanism of action: Prostaglandin analogues • Enhances uveoscleral outflow.

  3. Topical glaucoma medication with a yellowcap? • non-selective beta blockers 0.50% • Timoptic® (timolol) • Betagan® (levobunolol) • β2 selective beta blockers 0.50% • Betoptic S® (betaxolol)

  4. Topical glaucoma medication with a blue cap? • non-selective beta blockers 0.25% • Timoptic® (timolol) • Betagan® (levobunolol) • β2 selective beta blockers 0.25% • Betoptic S® (betaxolol)

  5. Mechanism of action of beta blockers? • reduces aqueous production (by blocking beta-2 receptors on nonpigmentedciliary epithelium)

  6. Topical glaucoma medication with a purple cap? • α2 adrenergic agonists • Iopidine® (apraclonidine) • 0.5% tid • 1.0% bid • Alphagan-P® (brimonidine) • 0.1% • 0.15% • 0.2% • bid or tid

  7. Mechanism of action for α2 adrenergic agonists • decreases aqueous production • increases uveoscleral outflow • “Both kinds of glaucoma treatment!”

  8. topical glaucoma medication with a green cap? • Cholinergic agonists (miotics) • pilocarpine (0.25% -- 10%) 2% or 4% most often. • carbachol • echothiophate

  9. Mechanism of action for cholinergic agonists • increases trabecular outflow • mayincreasuveoscleral outflow

  10. Topical glaucoma medication with an orange cap? • carbonic anhydrase inhibitors (CAIs) • Trusopt® (dorzolamide) 2% • Azopt® (brinzolamide) 1%

  11. Mechanism of action for carbonic anhydrase inhibitors • decreases aqueous production

  12. Glaucoma medications that increase outflow • Uveoscleral: • prostaglandins • α2 adrenergic agonists • Trabecular: • cholinergic agonists / miotics

  13. Glaucoma medications that reduce aqueous production • β blockers • α2 adrenergic agonists • carbonic anhydrase inhibitors

  14. “Discussion” points for every glaucoma patient: • “controlling a risk factor (high eye pressure) for glaucoma” • “in hopes to prevent vision loss” • “no guarantee that vision loss will not occur” • “like controlling (blood pressure) a risk factor for heart attack and stroke”

  15. Glaucoma standard of care • dilation with retinal biomiscropy • Goldmanntonometry • visual fields • gonioscopy • pachymetry • photography • (debatable) OCT/GDx/HRT

  16. OHTS  goals of study • Ocular Hypertension Treatment Study • Evaluate safety / efficacy of topical glaucoma medications • to prevent or delay congenital open angle glaucoma (COAG) in patients with high IOP • identify baseline demographic and clinical factors • predict which patients will develop COAG

  17. Ocular Hypertension Treatment Study (OHTS) • OHTS  Enrollees • patients with: • high IOP • normal visual fields (VF) • normal discs • patient randomly assigned to medical treatment or observation • patient monitored: • VF q 6 months • fundus photos q year • endpoint of COAG: • VF evidence • disc evidence • or both VF and disc evidence

  18. Ocular Hypertension Treatment Study (OHTS) • OHTS  results • COAG patients: • 55% diagnosed via disc changes without VF changes • 20% reduction in IOP decreased incidence of COAG by 50% at 5 years • black people developed COAG at significantly higher rate

  19. Ocular Hypertension Treatment Study (OHTS) • OHTS Important risk factors for glacomatous damage in ocular hypertensives • higher IOP • old age • large C/D • greater pattern standard deviation • thin central cornea thickness (CCT)

  20. Ocular Hypertension Treatment Study (OHTS) • OHTS  central corneal thickness (CCT) findings • patients with CCT less than 555 are 3x more likely to develop POAG • Much bigger risk factor than: • race • family history • refractive error • general health • Recommendation: pachymetry as standard part of evaluation of ocular hypertensive patients.

  21. Ocular Hypertension Treatment Study (OHTS) • OHTS  Guidelines • IOP: • 23.75 or below  low risk • 23.75 < IOP < 25.75  moderate risk • above 25.75  high risk • CCT (pachymetry): • above 588  low risk • 555 < CCT < 588  moderate risk • 555 or below  high risk • vertical C/D • 0.3 or less  low risk • 0.3 < C/D < 0.5  moderate risk • 0.5 or above  high risk

  22. In glaucoma, NFL damage precedes… • field loss and disc changes • 5 year, 50% “rule”  50% of NFL is lost before a VF will reveal a defect. • “we are in the business of preventing any vision loss”

  23. Instruments commonly used to manage patients with glaucoma • HRT2 – Heidelbert Retinal Tomograph • Stratus OCT – Optical Coherence Tomography from Zeiss Humphrey • GDx-VCC nerve fiber analyzer (with variable corneal compensator from Laser Diagnostic Technologies)

  24. HRT, OCT, GDx factoids • image the optic disc and/or retinal NFL • each has strengths & weaknesses • useful for glaucoma suspects  moderate glaucoma patients • NOT helpful for advanced glaucoma patients • cost: HRT < GDx < OCT

  25. Optic nerve imaging  considerations • imaging reimbursable at least once a year, HOWEVER, cannot be reimbursed for fundus photos & imaging on same day. • results need to be used within a larger clinical context! • ONH tissue, VF defects and imaging should all correlate & “make sense”

  26. HRT strengths & “considerations” • The HRT utilizes confocal scanning laser ophthalmoscopy • Strengths • shows topography of optic nerve • detects patient progression • confirms nerve size • evaluates cupping • “Considerations” • accuracy depends on drawing contour line correctly the first time. • probably not the best for assessing thickness of RNFL

  27. OCT strengths & “considerations” • OCT uses optical back scattering of light to compute tomographic images based on amount of incident light reflected by tissue. • Strengths • accurately measures RNFL thickness • correlates highly with VF loss & disc damage • reproducible • image quality monitored during test • awesome for macular holes, edema  CNV mgmt • reason why less fewer FLANs done at UMSL • “Considerations” • automatically generated disc contour lies can be somewhat inaccurate • does not determine progression • difficult to determine how much change is clinically significant • requires dilated pupil, minimal media opacity

  28. GDx strengths & “considerations” • GDx uses a scanning laser polarimeter • Strengths • measures RNFL • very reliable • portable • can do undilated • media opacities least likely to interfere • Considerations • image quality cannot be measured during test

  29. GDx NFL analysis • Gives ‘NFI’ number: • 0—30  normal, low probability of glaucoma • 31—70  glaucoma suspect • 71—100  high probability of glaucoma • The NFI number does NOT indicate severity or progression of glaucoma.

More Related